



NDA 218379

NDA APPROVAL

ADVENTAPHARMA DWC LLC
c/o Zydus Pharmaceuticals (USA) Inc.
73-B Route 31 North
Pennington, NJ 08534

Attention: Srinivas Gurram, Senior Vice President-Head of RA and CQA lead
U.S. Agent

Dear Srinivas Gurram:

Please refer to your new drug application (NDA) received February 23, 2023, and your amendments, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Zueino (diclofenac sodium) injection.

We acknowledge receipt of your amendment dated March 27, 2026, which constituted a complete response to our December 22, 2023, action letter.

This NDA provides for the use of Zueino (diclofenac sodium) injection for management of mild to moderate pain and the management of moderate to severe pain alone or in combination with opioid analgesics.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* (October 2009).²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to guidance for industry *SPL Standard for Content of Labeling Technical Qs & As* (DATE). For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 218379.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Zueino (diclofenac sodium) injection shall be 24 months from the date of manufacture when stored at 20°–25°C (68°–77° F).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs* (April 2022).³

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication,

² <https://www.fda.gov/media/71211/download>

³ <https://www.fda.gov/media/128163/download>

accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website⁶.

If you have any questions, contact Kimberly Compton, RPh, MS, RAC, Senior Regulatory Project Manager, at 301-796-1191 or via email at Kimberly.compton@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tina Doshi, MD, MHS
Deputy Director
Division of Anesthesiology, Addiction
Medicine, and Pain Medicine
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling-Prescribing Information
- Carton and Container Labeling

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

⁶ <https://www.uspnf.com/>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TINA TUONG-VI L DOSHI
09/25/2026 03:10:43 PM